JP2010539146A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539146A5 JP2010539146A5 JP2010524542A JP2010524542A JP2010539146A5 JP 2010539146 A5 JP2010539146 A5 JP 2010539146A5 JP 2010524542 A JP2010524542 A JP 2010524542A JP 2010524542 A JP2010524542 A JP 2010524542A JP 2010539146 A5 JP2010539146 A5 JP 2010539146A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- hydrate
- ester
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 14
- 238000000034 method Methods 0.000 claims 11
- 150000002148 esters Chemical class 0.000 claims 10
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- -1 hydrate Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003891 oxalate salts Chemical class 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical group OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- MRKOHQZPQWGPLB-UHFFFAOYSA-N CC(C)N(C)c1nc(NC(CO)CO)nc(NCc(cc2)ccc2-c2ccccn2)c1N=C Chemical compound CC(C)N(C)c1nc(NC(CO)CO)nc(NCc(cc2)ccc2-c2ccccn2)c1N=C MRKOHQZPQWGPLB-UHFFFAOYSA-N 0.000 description 2
- 0 CCC(C*C(C(C(C)C)N)=O)NC(*/C(/NCc(cc1)ccc1-c1ccccn1)=C1\N=C)C=C=C=C1N(C)C(C)C Chemical compound CCC(C*C(C(C(C)C)N)=O)NC(*/C(/NCc(cc1)ccc1-c1ccccn1)=C1\N=C)C=C=C=C1N(C)C(C)C 0.000 description 2
- UQXNNSSAAXGTCY-GYRAYZOKSA-N CC(C)CC(C(OC/C(/Nc(nc1N(C)C(C)C)nc(NCc(cc2)ccc2-c2ccccn2)c1N=C)=C/C)=O)N Chemical compound CC(C)CC(C(OC/C(/Nc(nc1N(C)C(C)C)nc(NCc(cc2)ccc2-c2ccccn2)c1N=C)=C/C)=O)N UQXNNSSAAXGTCY-GYRAYZOKSA-N 0.000 description 1
- WGNHOKURHRKYRO-BMZIXDSZSA-N CC(C)N(C1NC(N[C@H](CO)[C@@H](C)O)=NC(NCc(cc2)ccc2-c2ccccn2)=C1N)C=C Chemical compound CC(C)N(C1NC(N[C@H](CO)[C@@H](C)O)=NC(NCc(cc2)ccc2-c2ccccn2)=C1N)C=C WGNHOKURHRKYRO-BMZIXDSZSA-N 0.000 description 1
- NHKMFFNUYFVAFL-SFSWLVPXSA-N CC(C)N1C=NC2C1(C)NC(N[C@H](CCO)[C@@H](C)O)=NC2NCc(cc1)ccc1-c1ccccn1 Chemical compound CC(C)N1C=NC2C1(C)NC(N[C@H](CCO)[C@@H](C)O)=NC2NCc(cc1)ccc1-c1ccccn1 NHKMFFNUYFVAFL-SFSWLVPXSA-N 0.000 description 1
- HIJIAADNZXIJBE-QFIPXVFZSA-N CC(C)[C@H](CO)Nc(nc1N(C)C(C)C)nc(NCc(cc2)ccc2-c2ncccc2)c1N=C Chemical compound CC(C)[C@H](CO)Nc(nc1N(C)C(C)C)nc(NCc(cc2)ccc2-c2ncccc2)c1N=C HIJIAADNZXIJBE-QFIPXVFZSA-N 0.000 description 1
- KORMOHIBSWURFV-NRFANRHFSA-N CC(C)[C@H](CO)Nc1nc(NCc(cc2)ccc2-c2ncccc2)c2nc[n](C(C)C)c2n1 Chemical compound CC(C)[C@H](CO)Nc1nc(NCc(cc2)ccc2-c2ncccc2)c2nc[n](C(C)C)c2n1 KORMOHIBSWURFV-NRFANRHFSA-N 0.000 description 1
- QBHAKYUOIFLNCC-KLUPYSMESA-N CC(C)[C@H](CO)Nc1nc(NCc(cc2)ccc2/C(/N)=C/C=C\C=[IH])c2nc[n](C(C)C)c2n1 Chemical compound CC(C)[C@H](CO)Nc1nc(NCc(cc2)ccc2/C(/N)=C/C=C\C=[IH])c2nc[n](C(C)C)c2n1 QBHAKYUOIFLNCC-KLUPYSMESA-N 0.000 description 1
- BHWFYXCEKMPJIZ-NRFANRHFSA-O CC(C)[C@H](CO)Nc1nc(NCc(cc2)ccc2C2=CCCC=[NH+]2)c2nc[n](C(C)C)c2n1 Chemical compound CC(C)[C@H](CO)Nc1nc(NCc(cc2)ccc2C2=CCCC=[NH+]2)c2nc[n](C(C)C)c2n1 BHWFYXCEKMPJIZ-NRFANRHFSA-O 0.000 description 1
- GKRXRQZDDJHENX-UHFFFAOYSA-N CC(C)[n]1c2nc(NC(CO)CO)nc(NCc(cc3)ccc3-c3ncccc3)c2nc1 Chemical compound CC(C)[n]1c2nc(NC(CO)CO)nc(NCc(cc3)ccc3-c3ncccc3)c2nc1 GKRXRQZDDJHENX-UHFFFAOYSA-N 0.000 description 1
- ISAHPUXAGMKZCL-WPWMEQJKSA-N CC/C(/Nc1nc(NCc(cc2)ccc2C2=CC=CC=CC2=C)c2nc[n](C(C)C)c2c1)=C\CC(C(C(C)C)N)=O Chemical compound CC/C(/Nc1nc(NCc(cc2)ccc2C2=CC=CC=CC2=C)c2nc[n](C(C)C)c2c1)=C\CC(C(C(C)C)N)=O ISAHPUXAGMKZCL-WPWMEQJKSA-N 0.000 description 1
- HMPLQRRPQHZRHQ-UHFFFAOYSA-N CCC(CC=O)Nc1nc(NCc(cc2)ccc2-c2ncccc2)c2nc[n](C(C)C)c2n1 Chemical compound CCC(CC=O)Nc1nc(NCc(cc2)ccc2-c2ncccc2)c2nc[n](C(C)C)c2n1 HMPLQRRPQHZRHQ-UHFFFAOYSA-N 0.000 description 1
- BRJSFOFBYVFKCP-UHFFFAOYSA-N CCC(CO)Nc1nc(NCc(cc2)ccc2-c2ccccc2)c2nc[n](C(C)C)c2n1 Chemical compound CCC(CO)Nc1nc(NCc(cc2)ccc2-c2ccccc2)c2nc[n](C(C)C)c2n1 BRJSFOFBYVFKCP-UHFFFAOYSA-N 0.000 description 1
- HOCBJBNQIQQQGT-UHFFFAOYSA-N CCC(CO)Nc1nc(NCc(cc2)ccc2-c2ncccc2)c2nc[n](C(C)C)c2n1 Chemical compound CCC(CO)Nc1nc(NCc(cc2)ccc2-c2ncccc2)c2nc[n](C(C)C)c2n1 HOCBJBNQIQQQGT-UHFFFAOYSA-N 0.000 description 1
- HOCBJBNQIQQQGT-LJQANCHMSA-N CC[C@H](CO)Nc1nc(NCc(cc2)ccc2-c2ccccn2)c2nc[n](C(C)C)c2n1 Chemical compound CC[C@H](CO)Nc1nc(NCc(cc2)ccc2-c2ccccn2)c2nc[n](C(C)C)c2n1 HOCBJBNQIQQQGT-LJQANCHMSA-N 0.000 description 1
- CXTFOKMLJKQWNL-SYIFMXBLSA-N CC[C@H](Nc1nc(NCc(cc2)ccc2-c2ccccn2)c2nc[n](C(C)C)c2n1)NOC(C(C=C(C)C)N)=O Chemical compound CC[C@H](Nc1nc(NCc(cc2)ccc2-c2ccccn2)c2nc[n](C(C)C)c2n1)NOC(C(C=C(C)C)N)=O CXTFOKMLJKQWNL-SYIFMXBLSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0706390A FR2920776B1 (fr) | 2007-09-12 | 2007-09-12 | Utilisation de derives de purine pour la fabrication d'un medicament |
| FR0706390 | 2007-09-12 | ||
| PCT/FR2008/001278 WO2009068761A2 (fr) | 2007-09-12 | 2008-09-12 | Utilisation de derives de purine pour la fabrication d'un medicament |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539146A JP2010539146A (ja) | 2010-12-16 |
| JP2010539146A5 true JP2010539146A5 (enExample) | 2012-03-22 |
| JP5485893B2 JP5485893B2 (ja) | 2014-05-07 |
Family
ID=39382006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524542A Expired - Fee Related JP5485893B2 (ja) | 2007-09-12 | 2008-09-12 | 医薬品の製造のためにプリン誘導体を使用する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8431583B2 (enExample) |
| EP (1) | EP2187889B1 (enExample) |
| JP (1) | JP5485893B2 (enExample) |
| KR (1) | KR20100075908A (enExample) |
| CN (1) | CN101918000B (enExample) |
| BR (1) | BRPI0816810A2 (enExample) |
| CA (1) | CA2699590A1 (enExample) |
| DK (1) | DK2187889T3 (enExample) |
| ES (1) | ES2444419T3 (enExample) |
| FR (1) | FR2920776B1 (enExample) |
| MX (1) | MX2010002680A (enExample) |
| RU (1) | RU2500400C2 (enExample) |
| WO (1) | WO2009068761A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2920776B1 (fr) | 2007-09-12 | 2012-09-28 | Centre Nat Rech Scient | Utilisation de derives de purine pour la fabrication d'un medicament |
| WO2010103473A1 (en) * | 2009-03-10 | 2010-09-16 | Chu De Brest | Method of treatment of polycystic diseases and chronic lymphocytic leukemia |
| WO2013130461A1 (en) * | 2012-02-29 | 2013-09-06 | The Scripps Research Institute | Wee1 degradation inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| US6627633B2 (en) * | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
| US6969720B2 (en) * | 1999-03-17 | 2005-11-29 | Amr Technology, Inc. | Biaryl substituted purine derivatives as potent antiproliferative agents |
| DE60205376T2 (de) * | 2001-06-27 | 2006-04-06 | Cyclacel Ltd. | 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten |
| US6812232B2 (en) * | 2001-09-11 | 2004-11-02 | Amr Technology, Inc. | Heterocycle substituted purine derivatives as potent antiproliferative agents |
| US6667311B2 (en) * | 2001-09-11 | 2003-12-23 | Albany Molecular Research, Inc. | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
| GB0315259D0 (en) | 2003-06-30 | 2003-08-06 | Cyclacel Ltd | Use |
| AU2004264419B2 (en) * | 2003-08-15 | 2009-01-15 | Irm Llc | 6-substituted anilino purines as RTK inhibitors |
| FR2920776B1 (fr) | 2007-09-12 | 2012-09-28 | Centre Nat Rech Scient | Utilisation de derives de purine pour la fabrication d'un medicament |
-
2007
- 2007-09-12 FR FR0706390A patent/FR2920776B1/fr active Active
-
2008
- 2008-09-12 KR KR1020107007886A patent/KR20100075908A/ko not_active Ceased
- 2008-09-12 WO PCT/FR2008/001278 patent/WO2009068761A2/fr not_active Ceased
- 2008-09-12 CN CN2008801067270A patent/CN101918000B/zh not_active Expired - Fee Related
- 2008-09-12 MX MX2010002680A patent/MX2010002680A/es active IP Right Grant
- 2008-09-12 BR BRPI0816810A patent/BRPI0816810A2/pt not_active IP Right Cessation
- 2008-09-12 JP JP2010524542A patent/JP5485893B2/ja not_active Expired - Fee Related
- 2008-09-12 CA CA2699590A patent/CA2699590A1/fr not_active Abandoned
- 2008-09-12 ES ES08855583.4T patent/ES2444419T3/es active Active
- 2008-09-12 RU RU2010108505/15A patent/RU2500400C2/ru not_active IP Right Cessation
- 2008-09-12 US US12/675,945 patent/US8431583B2/en not_active Expired - Fee Related
- 2008-09-12 DK DK08855583.4T patent/DK2187889T3/da active
- 2008-09-12 EP EP08855583.4A patent/EP2187889B1/fr not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014500861A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| JP2006514626A5 (enExample) | ||
| JP2010095546A5 (enExample) | ||
| JP2011500550A5 (enExample) | ||
| JP2006526031A5 (enExample) | ||
| JP2009143956A5 (enExample) | ||
| JP2006509749A5 (enExample) | ||
| JP2009535462A5 (enExample) | ||
| EP2592070A3 (en) | Tetrazole-substituted arylamides | |
| JP2011518833A5 (enExample) | ||
| JP2010535722A5 (enExample) | ||
| JP2009543795A5 (enExample) | ||
| JP2012532848A5 (enExample) | ||
| JP2005520923A5 (enExample) | ||
| JP2005536519A5 (enExample) | ||
| JP2007519721A5 (enExample) | ||
| JP2013532130A5 (enExample) | ||
| JP2010529994A5 (enExample) | ||
| JP2012507535A5 (enExample) | ||
| JP2008536833A5 (enExample) | ||
| JP2010510232A5 (enExample) | ||
| RU2012144438A (ru) | Производные 1-(2-фторбифенил-4-ил)-алкилкарбоновой кислоты для лечения транстиретинового амилоидоза | |
| JP2010534246A5 (enExample) | ||
| JP2013513607A5 (enExample) |